Biomarkers

The effect of different preanalytical conditions on the stability of blood biomarkers in the diagnosis of Alzheimer’s disease

by
Clin Chem Lab Med - Mansilla et al. 2023

Stability of plasma samples and Alzheimer’s biomarkers Alzheimer’s disease is considered one of the most common causes of dementia in the elderly. Recently, blood biomarkers: Aβ1-42, Aβ1-40 and phospho Tau181 (p-Tau181), are proving useful in the diagnosis of the disease in research studies, but their analytical stability is unknown. A joint study between the Memory … Read more

Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist

by
blood-based biomarkers in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more

Multimarker synaptic panels for FTD

by

Multimarker panels in FTD Frontotemporal dementia is the most common cause of early-onset dementia and the principal cause of FrontoTemporal Lobular Degeneration (FTLD). Approximately, 90–95% of FTLD cases are characterized by the accumulation in the brain of two different proteins – tau and transactive response DNA-binding protein-43 (TDP-43). These protein inclusions lead to a loss of … Read more

Stability of Alzheimer biomarkers in CSF

by
Alzheimer - Sant Pau Memory Unit - Barcelona

Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal fluid biomarkers now play an important role in the diagnostic process. Two important neuropathological features of Alzheimer’s are the … Read more

Concordance between amyloid markers in CSF

by
Delaby Sant Pau Memory Unit - Barcelona

Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more

GFAP in blood helps predict the evolution of frontotemporal dementia

by

GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the advances in the diagnosis of frontotemporal dementia in the last two decades, we still do not have a precise marker for … Read more